Andrea Facciabene, Ph.D.
Research Assistant Professor of Obstetrics and Gynecology
Ovarian Cancer Research Center
Perelman School of Medicine
University of Pennsylvania
Mitochondria an eukaryotic commensal as new source of Tumor Associated Antigen
Recent approaches to drug discoveries focus upon the better understanding of the biochemical pathways that govern the pathogenesis of diseases at a molecular level. Previous studies have shown that malignant cells of many cancers expressed on their surface in high density, a genomic product VPAC1 combined for vasoactive intestinal and pituitary adenylate cyclase activating peptide. These finger prints, the receptors, encode G protein, involved in cell proliferation, differentiation and cell survival. On benign or normal cells, only a few VPAC1 receptors are present. We therefore hypothesized that targeting VPAC1 using a specific biomolecule labeled with a positron emitting radionuclide will permit us not only to image early cancers of the breast (BC), prostate (PC) and lung (LC), but will also distinguish benign lesions from malignant masses. Early data shall be presented.
After completing this activity, participants should be able to:
• Apply the latest clinical guidelines in the management of endocrine diseases • Evaluate and efficacy of therapeutic options in endocrine disorders • Describe the results of translational research as it pertains to endocrine diseases
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.